Background
The rapid and accurate diagnosis of individuals with SARS-CoV-2 infection is an effective way to prevent and control the spread of COVID-19. Although the detection of SARS-CoV‐2 viral RNA by RT‐qPCR is the gold standard for COVID‐19 testing, the use of antigen-detecting rapid diagnostic tests (Ag-RDTs) is emerging as a complementary surveillance tool as Omicron case numbers skyrocket worldwide. However, the results from Ag-RDTs are less accurate for individuals with low viral loads.
Methods
To develop a more sensitive and accurate Ag-RDT, we screened a total of 90 candidate monoclonal antibodies (mAbs) obtained from guinea pigs immunized with SARS-CoV-2 nucleocapsid protein (CoV-2-NP), and a highly specific epitope-characterized mAb set suitable for detecting the antigen was selected. By applying the mAb set to an automated chemiluminescence flow-through membrane immunoassay device, we developed a highly sensitive and quantitative Ag-RDT, CoV-2-POCube.
Results
CoV-2-POCube exclusively recognizes a variety of CoV-2-NP variants but not the nucleocapsid proteins of SARS-CoV and other human coronaviruses. CoV-2-POCube achieved a limit of detection sensitivity of 0.20 ~ 0.66 pg/mL of a variety of CoV-2-NP variants, showing over 100 times greater sensitivity than commercially airable SARS-CoV-2 Ag-RDTs.
Conclusion
CoV-2-POCube is a promising alternative to currently available diagnostic devices for faster clinical decision-making in individuals with suspected COVID-19 in limited-resource settings.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.